Elevance Health raises full-year profit outlook as medical costs ease
Elevance Health is lifting its annual earnings guidance after third-quarter results come in stronger than expected, reflecting improving profitability in its insurance operations. The company also signals that 2027 adjusted earnings are set to rise above current Wall Street forecasts as it builds on a lower medical cost trend.
Highlights
- Elevance Health boosted its 2026 earnings guidance by $2 per share after a stronger-than-expected third quarter and easing medical costs.
- Adjusted earnings for 2027 are projected to rise by at least 12% from a new $26.75 per share baseline, excluding certain 2023 items.
- Elevance forecasts 2024 earnings will exceed Wall Street estimates, reflecting improved margin confidence amid more favorable medical cost trends in managed care.
Updated earnings outlook and 2027 target
As reported by Bloomberg, Elevance Health increased its 2026 earnings guidance by $2 a share after a stronger-than-expected third quarter and lower medical costs that support margins in its insurance business.The company says in a presentation on Wednesday that adjusted earnings in 2027 will increase by at least 12% from a new baseline of $26.75 a share. That baseline excludes some current-year items, giving investors a revised starting point for next year's growth expectations.
Implications for the healthcare insurance sector
The updated outlook points to rising confidence at one of the largest U.S. healthcare companies as it works to rebuild profits across its insurance operations and health services arm.Elevance's projection that next year's earnings will top current Wall Street estimates suggests a more favorable cost environment for managed care companies, particularly as investors watch medical expense trends closely across the sector.
Our earlier coverage looked at how the S&P 500’s push toward the 8,000 level was increasingly tied to the market’s ability to deliver very strong third-quarter earnings amid headwinds like higher oil prices, elevated Treasury yields, and political uncertainty. We also noted growing concerns about narrow market breadth and concentration in a small group of megacaps, even as forecasts for overall earnings growth remained robust.